35 related articles for article (PubMed ID: 11011333)
21. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.
Dunn CJ; Foster RH
Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797
[TBL] [Abstract][Full Text] [Related]
22. Why diabetics are at risk in percutaneous coronary intervention and the appropriate management of diabetics in interventional cardiology.
Reginelli JP; Bhatt DL
J Invasive Cardiol; 2002 Dec; 14 Suppl E():2E-10E; quiz 11E. PubMed ID: 12668857
[TBL] [Abstract][Full Text] [Related]
23. Restenosis: the cost to society.
Califf RM
Am Heart J; 1995 Sep; 130(3 Pt 2):680-4. PubMed ID: 7668217
[TBL] [Abstract][Full Text] [Related]
24. A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists.
Robinson M; Ginnelly L; Sculpher M; Jones L; Riemsma ; Palmer S; Philips Z; Glanville J
Health Technol Assess; 2002; 6(25):1-160. PubMed ID: 12583818
[No Abstract] [Full Text] [Related]
25. Current perspectives on interventional treatment strategies in diabetic patients with coronary artery disease.
Kornowski R; Lansky AJ
Catheter Cardiovasc Interv; 2000 Jun; 50(2):245-54. PubMed ID: 10842400
[TBL] [Abstract][Full Text] [Related]
26. A concise review of the cost-effectiveness of coronary heart disease prevention.
Brown AI; Garber AM
Med Clin North Am; 2000 Jan; 84(1):279-97, xi. PubMed ID: 10685140
[TBL] [Abstract][Full Text] [Related]
27. Abciximab provides cost-effective survival advantage in high-volume interventional practice.
Kereiakes DJ; Obenchain RL; Barber BL; Smith A; McDonald M; Broderick TM; Runyon JP; Shimshak TM; Schneider JF; Hattemer CR; Roth EM; Whang DD; Cocks D; Abbottsmith CW
Am Heart J; 2000 Oct; 140(4):603-10. PubMed ID: 11011333
[TBL] [Abstract][Full Text] [Related]
28. Abciximab: cost-effective survival advantage in clinical trials and clinical practice.
Young JJ; Kereiakes DJ
Am Heart J; 2000 Dec; 140(6 Suppl):S148-53. PubMed ID: 11100009
[TBL] [Abstract][Full Text] [Related]
29. Abciximab therapy in percutaneous intervention: economic issues in the United States.
Goklaney AK; Murphy JD; Hillegass WB
Eur Heart J; 1998 Apr; 19 Suppl D():D52-8. PubMed ID: 9597522
[TBL] [Abstract][Full Text] [Related]
30. The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era.
Adelman AG; Caramori PR; Cohen EA; Chisholm RJ; Côté G; Ducas J; O'Neill BJ; Tcheng JE
Can J Cardiol; 1998 Aug; 14(8):1057-66. PubMed ID: 9738165
[TBL] [Abstract][Full Text] [Related]
31. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
Exaire JE; Lincoff AM
J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958
[No Abstract] [Full Text] [Related]
32. Abciximab therapy in percutaneous intervention: economic issues in the United States.
Goklaney AK; Murphy JD; Hillegass WB
Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
